Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty

Authors not listed

Longeveron Inc. · 2014

Abstract

The purpose of this study is to look at the safety of treatment with stem cells in patients with Frailty.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-08 MST

Cite this

APA
Anonymous. (2014). A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty. <em>Longeveron Inc.</em>. https://clinicaltrials.gov/study/NCT02065245
Vancouver
Anonymous. A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty. Longeveron Inc.. 2014.
BibTeX
@misc{anon2014APhase, title = {A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty}, author = {Anonymous}, journal = {Longeveron Inc.}, year = {2014}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings